Search Results - "Kiladjian, JJ"

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet by Barbui, Tiziano, Tefferi, Ayalew, Vannucchi, Alessandro M., Passamonti, Francesco, Silver, Richard T., Hoffman, Ronald, Verstovsek, Srdan, Mesa, Ruben, Kiladjian, Jean-Jacques, Hehlmann, Rȕdiger, Reiter, Andreas, Cervantes, Francisco, Harrison, Claire, Mc Mullin, Mary Frances, Hasselbalch, Hans Carl, Koschmieder, Steffen, Marchetti, Monia, Bacigalupo, Andrea, Finazzi, Guido, Kroeger, Nicolaus, Griesshammer, Martin, Birgegard, Gunnar, Barosi, Giovanni

“…This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by…”
Get full text

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet by BARBUI, Tiziano, BAROSI, Giovanni, KILADJIAN, Jean-Jacques, KRÖGER, Nicolaus, MESA, Ruben, MCMULLIN, Mary F, PARDANANI, Animesh, PASSAMONTI, Francesco, VANNUCCHI, Alessandro M, REITER, Andreas, SILVER, Richard T, VERSTOVSEK, Srdan, BIRGEGARD, Gunnar, TEFFERI, Ayalew, CERVANTES, Francisco, FINAZZI, Guido, GRIESSHAMMER, Martin, HARRISON, Claire, HASSELBALCH, Hans Carl, HEHLMANN, Rudiger, HOFFMAN, Ronald

“…We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms,…”
Get full text

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis by Smalberg, Jasper H., Arends, Lidia R., Valla, Dominique C., Kiladjian, Jean-Jacques, Janssen, Harry L.A., Leebeek, Frank W.G.

“…Myeloproliferative neoplasms (MPNs) are the most common cause of Budd-Chiari syndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT). In…”
Get full text

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs by EMANUEL, Robyn M, DUECK, Amylou C, FUENTES, Ana Kerguelen, HERNANDEZ-MARAVER, Dolores, PAHL, Heike L, GRIESSHAMMER, Martin, STEGELMANN, Frank, DOEHNER, Konstanze, LEHMANN, Thomas, BONATZ, Karin, REITER, Andreas, BOYER, Francoise, GEYER, Holly L, ETIENNE, Gabriel, IANOTTO, Jean-Christophe, RANTA, Dana, ROY, Lydia, CAHN, Jean-Yves, HARRISON, Claire N, RADIA, Deepti, MUXI, Pablo, MALDONADO, Norman, BESSES, Carlos, KILADJIAN, Jean-Jacques, CERVANTES, Francisco, JOHANSSON, Peter L, BARBUI, Tiziano, BAROSI, Giovanni, VANNUCCHI, Alessandro M, PASSAMONTI, Francesco, ANDREASSON, Bjorn, FERARRI, Maria L, RAMBALDI, Alessandro, SAMUELSSON, Jan, SLOT, Stefanie, BIRGEGARD, Gunnar, TEFFERI, Ayalew, MESA, Ruben A, ZWEEGMAN, Sonja, TE BOEKHORST, Peter A. W, COMMANDEUR, Suzan, SCHOUTEN, Harry C, SACKMANN, Federico

“…Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the…”
Get full text

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project by Barosi, Giovanni, Mesa, Ruben, Finazzi, Guido, Harrison, Claire, Kiladjian, Jean-Jacques, Lengfelder, Eva, McMullin, Mary F., Passamonti, Francesco, Vannucchi, Alessandro M., Besses, Carlos, Gisslinger, Heinz, Samuelsson, Jan, Verstovsek, Srdan, Hoffman, Ronald, Pardanani, Animesh, Cervantes, Francisco, Tefferi, Ayalew, Barbui, Tiziano

“…Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European…”
Get full text

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Vannucchi, A.M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J.-J., Kröger, N., Thiele, J., Buske, C.

Get full text

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial by Verstovsek, Srdan, Vannucchi, Alessandro M, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Kirito, Keita, Besses, Carlos, Hino, Masayuki, Moiraghi, Beatriz, Miller, Carole B, Cazzola, Mario, Rosti, Vittorio, Blau, Igor, Mesa, Ruben, Jones, Mark M, Zhen, Huiling, Li, Jingjin, Francillard, Nathalie, Habr, Dany, Kiladjian, Jean-Jacques

“…RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in…”
Get full text

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis by Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T

Get full text

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients by Geyer, Holly L., Scherber, Robyn M., Dueck, Amylou C., Kiladjian, Jean-Jacques, Xiao, Zhijian, Slot, Stefanie, Zweegman, Sonja, Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández-Maraver, Dolores, Döhner, Konstanze, Harrison, Claire N., Radia, Deepti, Muxi, Pablo, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L., Andreasson, Bjorn, Rambaldi, Alessandro, Barbui, Tiziano, Vannucchi, Alessandro M., Passamonti, Francesco, Samuelsson, Jan, Birgegard, Gunnar, Mesa, Ruben A.

“…Symptom burden in myeloproliferative neoplasms (MPNs) is heterogeneous even among patients within the same MPN diagnosis. Using cluster analysis from…”
Get full text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients by Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Get full text

Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status by Kiladjian, Jean-Jacques, Platzbecker, Uwe, Mayer, Jiří, Illés, Árpád, Prejzner, Witold, Woźny, Tomasz, Tzvetkov, Nikolay, Vannucchi, Alessandro M., Kirgner, Ilya, Nagy, Zsolt, Grosicki, Sebastian, Derolf, Åsa, Lazaroiu, Mihaela Cornelia, Yoon, Sung-Soo, Goh, Yeow Tee, von Bubnoff, Nikolas, Verstovsek, Srdan, Klencke, Barbara J., Donahue, Rafe, Mesa, Ruben A.

“…Abstract only e19039 Background: Momelotinib (MMB) is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the hallmark features of…”
Get full text

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group by Geyer, Holly L, Kosiorek, Heidi, Dueck, Amylou C, Scherber, Robyn, Slot, Stefanie, Zweegman, Sonja, Te Boekhorst, Peter Aw, Senyak, Zhenya, Schouten, Harry C, Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández-Maraver, Dolores, Pahl, Heike L, Griesshammer, Martin, Stegelmann, Frank, Döhner, Konstanze, Lehmann, Thomas, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Harrison, Claire N, Radia, Deepti, Muxi, Pablo, Maldonado, Norman, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L, Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M, Paoli, Chiara, Passamonti, Francesco, Andreasson, Bjorn, Ferrari, Maria L, Rambaldi, Alessandro, Samuelsson, Jan, Cannon, Keith, Birgegard, Gunnar, Xiao, Zhijian, Xu, Zefeng, Zhang, Yue, Sun, Xiujuan, Xu, Junqing, Kiladjian, Jean-Jacques, Zhang, Peihong, Gale, Robert Peter, Mesa, Ruben A

“…The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom…”
Get full text

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy by Mesa, Ruben, Verstovsek, Srdan, Kiladjian, Jean-Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N., Pane, Fabrizio, Zachee, Pierre, Zhen, Huiling, Jones, Mark M., Parasuraman, Shreekant, Li, Jingjin, Côté, Isabelle, Habr, Dany, Vannucchi, Alessandro M.

“…Objectives Polycythemia vera (PV)‐related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial…”
Get full text

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease by Geyer, Holly, Scherber, Robyn, Kosiorek, Heidi, Dueck, Amylou C, Kiladjian, Jean-Jacques, Xiao, Zhijian, Slot, Stefanie, Zweegman, Sonja, Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández-Maraver, Dolores, Döhner, Konstanze, Harrison, Claire N, Radia, Deepti, Muxi, Pablo, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L, Andreasson, Bjorn, Rambaldi, Alessandro, Barbui, Tiziano, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Maldonado, Norman, Barosi, Giovanni, Ferrari, Maria L, Gale, Robert Peter, Birgegard, Gunnar, Xu, Zefeng, Zhang, Yue, Sun, Xiujuan, Xu, Junqing, Zhang, Peihong, te Boekhorst, Peter A W, Commandeur, Suzan, Schouten, Harry, Pahl, Heike L, Griesshammer, Martin, Stegelmann, Frank, Lehmann, Thomas, Senyak, Zhenya, Vannucchi, Alessandro M, Passamonti, Francesco, Samuelsson, Jan, Mesa, Ruben A

“…Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications…”
Get full text

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients by GOWIN, Krisstina, THAPALIYA, Prakash, CAMORIANO, John, GENTRY, Amy, KILADJIAN, Jean-Jacques, O'CONNELL, Casey, MESA, Ruben, SAMUELSON, Jan, HARRISON, Claire, RADIA, Deepti, ANDREASSON, Bjorn, MASCARENHAS, John, RAMBALDI, Alessandro, BARBUI, Tiziano, REA, Catherine J

“…The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with…”
Get full text

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) by Barosi, G, Tefferi, A, Besses, C, Birgegard, G, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, Barbui, T

“…The discovery of somatic mutations, primarily JAK2 V617F and CALR , in classic BCR-ABL1 -negative myeloproliferative neoplasms (MPNs) has generated interest in…”
Get full text

NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome by Braun, Thorsten, Carvalho, Gabrielle, Coquelle, Arnaud, Vozenin, Marie-Catherine, Lepelley, Pascale, Hirsch, François, Kiladjian, Jean-Jacques, Ribrag, Vincent, Fenaux, Pierre, Kroemer, Guido

“…Myelodysplastic syndrome (MDS) is a preneoplastic condition that frequently develops into overt acute myeloid leukemia (AML). The P39 MDS/AML cell line…”
Get full text

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group by Geyer, Holly L., Andreasson, Bjorn, Kosiorek, Heidi E., Dueck, Amylou C., Scherber, Robyn M., Martin, Kari A., Butler, Kristina A., Harrison, Claire N., Radia, Deepti H., Cervantes, Francisco, Kiladjian, Jean‐Jacques, Reiter, Andreas, Birgegard, Gunnar, Passamonti, Francesco, Senyak, Zhenya, Vannucchi, Alessandro M., Paoli, Chiara, Xiao, Zhijian, Samuelsson, Jan, Mesa, Ruben A.

“…BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with…”
Get full text

Improved Transfusion Independence Rates for Momelotinib versus Ruxolitinib in Anaemic Jaki Naive Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status by Kiladjian, JJ, Platzbecker, U, Mayer, J, Illes, A, Prejzner, W, Wozny, T, Vannucchi, AM, Kirgner, I, Nagy, Z, Grosicki, S, Derolf, A, Lazaroiu, MC, Yoon, SS, Goh, YT, Von Bubnoff, N, Verstovsek, S, Strouse, B, Klencke, B, Donahue, R, Mesa, R

Get full text

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions by Aziz, Athar, Baxter, E Joanna, Edwards, Carol, Cheong, Clara Yujing, Ito, Mitsuteru, Bench, Anthony, Kelley, Rebecca, Silber, Yvonne, Beer, Philip A, Chng, Keefe, Renfree, Marilyn B, McEwen, Kirsten, Gray, Dionne, Nangalia, Jyoti, Mufti, Ghulam J, Hellstrom-Lindberg, Eva, Kiladjian, Jean-Jacques, McMullin, Mary Frances, Campbell, Peter J, Ferguson-Smith, Anne C, Green, Anthony R

“…Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis…”
Get full text